CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
58.78
+2.28 (4.04%)
At close: Mar 9, 2026, 4:00 PM EDT
56.53
-2.25 (-3.83%)
After-hours: Mar 9, 2026, 7:58 PM EDT

CRISPR Therapeutics AG Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Market Capitalization
5,6424,9983,3604,9723,1835,799
Upgrade
Market Cap Growth
37.29%48.76%-32.44%56.24%-45.12%-46.39%
Upgrade
Enterprise Value
3,8733,2641,6513,4741,4523,527
Upgrade
Last Close Price
58.7852.4439.3662.6040.6575.78
Upgrade
PE Ratio
-----15.36
Upgrade
PS Ratio
1607.411423.8090.0313.402656.646.34
Upgrade
PB Ratio
2.932.601.742.641.702.42
Upgrade
P/TBV Ratio
2.942.601.742.641.702.42
Upgrade
P/FCF Ratio
-----12.68
Upgrade
P/OCF Ratio
-----10.76
Upgrade
EV/Sales Ratio
1103.40930.0444.269.361211.763.86
Upgrade
EV/EBITDA Ratio
-----9.01
Upgrade
EV/EBIT Ratio
-----9.44
Upgrade
EV/FCF Ratio
-----7.71
Upgrade
Debt / Equity Ratio
0.110.110.120.130.130.09
Upgrade
Debt / EBITDA Ratio
-----0.53
Upgrade
Debt / FCF Ratio
-----0.49
Upgrade
Net Debt / Equity Ratio
-0.92-0.92-0.87-0.77-0.87-0.90
Upgrade
Net Debt / EBITDA Ratio
3.223.223.767.192.50-5.50
Upgrade
Net Debt / FCF Ratio
5.115.1111.615.403.05-4.71
Upgrade
Asset Turnover
0.000.000.020.1700.40
Upgrade
Quick Ratio
13.2513.2521.9717.4715.0819.92
Upgrade
Current Ratio
13.3213.3222.0717.5415.3020.17
Upgrade
Return on Equity (ROE)
-30.18%-30.18%-19.20%-8.17%-30.42%18.59%
Upgrade
Return on Assets (ROA)
-15.76%-15.76%-13.04%-6.22%-16.85%10.20%
Upgrade
Return on Invested Capital (ROIC)
-312.24%-280.87%-137.29%-60.81%-244.99%264.84%
Upgrade
Return on Capital Employed (ROCE)
-26.90%-26.90%-21.70%-10.50%-31.70%14.20%
Upgrade
Earnings Yield
-10.31%-11.64%-10.90%-3.09%-20.43%6.51%
Upgrade
FCF Yield
-6.13%-6.92%-4.31%-5.43%-16.74%7.89%
Upgrade
Buyback Yield / Dilution
-6.60%-6.60%-6.49%-1.90%3.29%-21.90%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.